tradingkey.logo

enVVeno Medical Corp

NVNO
0.689USD
+0.039+6.00%
Horário de mercado ETCotações atrasadas em 15 min
13.26MValor de mercado
PerdaP/L TTM

enVVeno Medical Corp

0.689
+0.039+6.00%

Mais detalhes de enVVeno Medical Corp Empresa

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.

Informações de enVVeno Medical Corp

Código da empresaNVNO
Nome da EmpresaenVVeno Medical Corp
Data de listagemMay 31, 2018
CEOMr. Robert A. Berman
Número de funcionários37
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 31
Endereço70 Doppler
CidadeIRVINE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92618
Telefone19492612900
Sitehttps://envveno.com/
Código da empresaNVNO
Data de listagemMay 31, 2018
CEOMr. Robert A. Berman

Executivos da empresa enVVeno Medical Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

Detalhamento da receita

Sem dados
Sem dados
Por Empresa
Por Região
Sem dados

Distribuição de ações

Atualizado em: sex, 31 de out
Atualizado em: sex, 31 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Kingdon Capital Management, L.L.C.
6.72%
Perceptive Advisors LLC
6.36%
The Vanguard Group, Inc.
3.45%
Nantahala Capital Management, LLC
2.94%
Westside Investment Management, LLC
1.38%
Outro
79.14%
Investidores
Investidores
Proporção
Kingdon Capital Management, L.L.C.
6.72%
Perceptive Advisors LLC
6.36%
The Vanguard Group, Inc.
3.45%
Nantahala Capital Management, LLC
2.94%
Westside Investment Management, LLC
1.38%
Outro
79.14%
Tipos de investidores
Investidores
Proporção
Hedge Fund
11.08%
Investment Advisor
7.41%
Private Equity
6.48%
Individual Investor
1.77%
Investment Advisor/Hedge Fund
1.55%
Research Firm
1.06%
Venture Capital
0.09%
Outro
70.56%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
75
5.53M
27.33%
-744.33K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Kingdon Capital Management, L.L.C.
1.36M
7.06%
+500.00K
+58.19%
Sep 02, 2025
Perceptive Advisors LLC
1.28M
6.68%
+1.28M
--
Jun 30, 2025
The Vanguard Group, Inc.
698.34K
3.63%
+97.43K
+16.21%
Jun 30, 2025
Nantahala Capital Management, LLC
594.66K
3.09%
--
--
Jun 30, 2025
Westside Investment Management, LLC
279.52K
1.45%
+20.48K
+7.90%
Jun 30, 2025
UBS O'Connor LLC
241.16K
1.25%
-54.87K
-18.54%
Jun 30, 2025
I.C.M. Investment Bank AG
200.00K
1.04%
+50.00K
+33.33%
Jun 30, 2025
Geode Capital Management, L.L.C.
199.51K
1.04%
+2.21K
+1.12%
Jun 30, 2025
J.P. Morgan Securities LLC
182.30K
0.95%
-11.91K
-6.13%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Data
Tipo
Proporção
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
KeyAI